A technology revolution is transforming the healthcare industry, changing everything from how patients are diagnosed and treated to our battle against some of the world’s most serious diseases. It’s a revolution fuelled by new sources of healthcare data and powered by big data analytics – and it’s being pushed even further by new developments in AI.
Between growing populations, ageing populations, drug-resistant microbes and pressures on staff and budgets, healthcare faces some enormous challenges. Yet with data, analytics and AI – supported by new cloud, storage and processor technologies – the industry is moving in the right direction to meet them. This revolution will change and save patients’ lives.
Exscientia is at the forefront of Artificial Intelligence-driven drug discovery and design. As at 8th January 2019, Frontier IP Group Plc (LON:FIPP) have a 3.3% holding in Exscientia. Frontier IP Group, through its subsidiaries, engages in assisting universities, research institutions, and companies in the commercialization and exploitation of their intellectual property (IP) in the United Kingdom.